| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Minireview |
Department of Medical Oncology and Hematology, Princess Margaret Hospital, University Health Network, Toronto, Ontario, M5G 2M9 Canada
3-Hydroxy-3-methylgutaryl CoA reductase inhibitors, commonly referred to as the statins, have proven therapeutic and preventative effects in cardiovascular diseases. Recently, there are emerging interests in their use as anticancer agents based on preclinical evidence of their antiproliferative, proapoptotic, anti-invasive, and radiosensitizing properties. Inhibition of 3-hydroxy-3-methylgutaryl CoA reductase by the statins interferes with the rate-limiting step of the mevalonate pathway, leading to reduced levels of mevalonate and its downstream products, many of which play important roles in critical cellular functions such as membrane integrity, cell signaling, protein synthesis, and cell cycle progression. Perturbations of these processes in neoplastic cells by the statins may therefore result in control of tumor initiation, growth, and metastasis. The statins have demonstrated growth inhibitory activity in cancer cell lines and preclinical tumor models in animals. Phase I trials of statins in humans have demonstrated myotoxicity as their main dose-limiting toxicity, and Phase II trials in various tumor types are ongoing to evaluate their efficacy. Potential future directions in the development of the statins as anticancer agents include combinations with chemotherapeutic or other molecular-targeted agents, combinations with radiotherapy, maintenance therapy in minimal disease status, and as chemopreventive therapy.
This article has been cited by other articles:
|
|
 |
|
  I. Agalliu, C. A. Salinas, P. D. Hansten, E. A. Ostrander, and J. L. Stanford Statin Use and Risk of Prostate Cancer: Results from a Population-based Epidemiologic Study Am. J. Epidemiol., August 1, 2008; 168(3): 250 - 260. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Woodard, A. Sassano, N. Hay, and L. C. Platanias Statin-Dependent Suppression of the Akt/Mammalian Target of Rapamycin Signaling Cascade and Programmed Cell Death 4 Up-Regulation in Renal Cell Carcinoma Clin. Cancer Res., July 15, 2008; 14(14): 4640 - 4649. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. S. Kumar, C. C. Benz, V. Shim, C. A. Minami, D. H. Moore, and L. J. Esserman Estrogen Receptor-Negative Breast Cancer Is Less Likely to Arise among Lipophilic Statin Users Cancer Epidemiol. Biomarkers Prev., May 1, 2008; 17(5): 1028 - 1033. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Black Jr. and P. C. Trackman Transforming Growth Factor-{beta}1 (TGF{beta}1) Stimulates Connective Tissue Growth Factor (CCN2/CTGF) Expression in Human Gingival Fibroblasts through a RhoA-independent, Rac1/Cdc42-dependent Mechanism: STATINS WITH FORSKOLIN BLOCK TGF{beta}1-INDUCED CCN2/CTGF EXPRESSION J. Biol. Chem., April 18, 2008; 283(16): 10835 - 10847. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Das, M. Schapira, M. Tomic-Canic, R. Goyanka, T. Cardozo, and H. H. Samuels Farnesyl Pyrophosphate Is a Novel Transcriptional Activator for a Subset of Nuclear Hormone Receptors Mol. Endocrinol., November 1, 2007; 21(11): 2672 - 2686. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. D. Flick, L. A. Habel, K. A. Chan, S. K. Van Den Eeden, V. P. Quinn, R. Haque, E. J. Orav, J. D. Seeger, M. C. Sadler, C. P. Quesenberry Jr., et al. Statin Use and Risk of Prostate Cancer in the California Men's Health Study Cohort Cancer Epidemiol. Biomarkers Prev., November 1, 2007; 16(11): 2218 - 2225. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Shachaf, O. D. Perez, S. Youssef, A. C. Fan, S. Elchuri, M. J. Goldstein, A. E. Shirer, O. Sharpe, J. Chen, D. J. Mitchell, et al. Inhibition of HMGcoA reductase by atorvastatin prevents and reverses MYC-induced lymphomagenesis Blood, October 1, 2007; 110(7): 2674 - 2684. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Sassano, E. Katsoulidis, G. Antico, J. K. Altman, A. J. Redig, S. Minucci, M. S. Tallman, and L. C. Platanias Suppressive Effects of Statins on Acute Promyelocytic Leukemia Cells Cancer Res., May 1, 2007; 67(9): 4524 - 4532. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Khurana, H. R. Bejjanki, G. Caldito, and M. W. Owens Statins Reduce the Risk of Lung Cancer in Humans: A Large Case-Control Study of US Veterans Chest, May 1, 2007; 131(5): 1282 - 1288. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R.-Y. Su, Y. Chao, T.-Y. Chen, D.-Y. Huang, and W.-W. Lin 5-Aminoimidazole-4-carboxamide riboside sensitizes TRAIL- and TNF{alpha}-induced cytotoxicity in colon cancer cells through AMP-activated protein kinase signaling Mol. Cancer Ther., May 1, 2007; 6(5): 1562 - 1571. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Boudreau, O. Yu, D. L. Miglioretti, D. S.M. Buist, S. R. Heckbert, and J. R. Daling Statin Use and Breast Cancer Risk in a Large Population-Based Setting Cancer Epidemiol. Biomarkers Prev., March 1, 2007; 16(3): 416 - 421. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. F. Coogan, J. Smith, and L. Rosenberg Statin Use and Risk of Colorectal Cancer J Natl Cancer Inst, January 3, 2007; 99(1): 32 - 40. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. R. Freeman, A. L. Drake, L. F. Heilig, M. Graber, K. McNealy, L. M. Schilling, and R. P. Dellavalle Statins, Fibrates, and Melanoma Risk: a Systematic Review and Meta-analysis. J Natl Cancer Inst, November 1, 2006; 98(21): 1538 - 1546. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Roudier, O. Mistafa, and U. Stenius Statins induce mammalian target of rapamycin (mTOR)-mediated inhibition of Akt signaling and sensitize p53-deficient cells to cytostatic drugs. Mol. Cancer Ther., November 1, 2006; 5(11): 2706 - 2715. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Bonovas, K. Filioussi, N. Tsavaris, and N. M. Sitaras Statins and Cancer Risk: A Literature-Based Meta-Analysis and Meta-Regression Analysis of 35 Randomized Controlled Trials J. Clin. Oncol., October 20, 2006; 24(30): 4808 - 4817. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Kim Statin and Cancer Risks: From Tasseomancy of Epidemiologic Studies to Meta-Analyses J. Clin. Oncol., October 20, 2006; 24(30): 4796 - 4797. [Full Text] [PDF]
|
|
|
|
|
|
M. J. Campbell, L. J. Esserman, Y. Zhou, M. Shoemaker, M. Lobo, E. Borman, F. Baehner, A. S. Kumar, K. Adduci, C. Marx, et al. Breast Cancer Growth Prevention by Statins. Cancer Res., September 1, 2006; 66(17): 8707 - 8714. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. K. Takahashi, G. Weitz-Schmidt, H. Iwagaki, T. Yoshino, N. Tanaka, and M. Nishibori Hypothesis: the antitumor activities of statins may be mediated by IL-18 J. Leukoc. Biol., August 1, 2006; 80(2): 215 - 216. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Dimitroulakos, I. A. Lorimer, and G. Goss Strategies to enhance epidermal growth factor inhibition: targeting the mevalonate pathway. Clin. Cancer Res., July 15, 2006; 12(14): 4426s - 4431s. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Boudreau, C. M. Rutter, and D. S.M. Buist The influence of statin use on breast density. Cancer Epidemiol. Biomarkers Prev., May 1, 2006; 15(5): 1026 - 1029. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. C. Li, M. J. Park, S.-K. Ye, C.-W. Kim, and Y.-N. Kim Elevated Levels of Cholesterol-Rich Lipid Rafts in Cancer Cells Are Correlated with Apoptosis Sensitivity Induced by Cholesterol-Depleting Agents Am. J. Pathol., April 1, 2006; 168(4): 1107 - 1118. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Chamilos, R. E. Lewis, and D. P. Kontoyiannis Lovastatin Has Significant Activity against Zygomycetes and Interacts Synergistically with Voriconazole Antimicrob. Agents Chemother., January 1, 2006; 50(1): 96 - 103. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Bonovas, K. Filioussi, N. Tsavaris, and N. M. Sitaras Use of Statins and Breast Cancer: A Meta-Analysis of Seven Randomized Clinical Trials and Nine Observational Studies J. Clin. Oncol., December 1, 2005; 23(34): 8606 - 8612. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Edelman, R. Smith, P. Hausner, L. A. Doyle, K. Kalra, J. Kendall, M. Bedor, and S. Bisaccia Phase II Trial of the Novel Retinoid, Bexarotene, and Gemcitabine Plus Carboplatin in Advanced Non-Small-Cell Lung Cancer J. Clin. Oncol., August 20, 2005; 23(24): 5774 - 5778. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Menendez, L. Vellon, and R. Lupu Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene Ann. Onc., August 1, 2005; 16(8): 1253 - 1267. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kucia, R. Reca, K. Miekus, J. Wanzeck, W. Wojakowski, A. Janowska-Wieczorek, J. Ratajczak, and M. Z. Ratajczak Trafficking of Normal Stem Cells and Metastasis of Cancer Stem Cells Involve Similar Mechanisms: Pivotal Role of the SDF-1-CXCR4 Axis Stem Cells, August 1, 2005; 23(7): 879 - 894. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Gullu, R. Emral, M. Bastemir, A. B Parkes, and J. H Lazarus In vivo and in vitro effects of statins on lymphocytes in patients with Hashimoto's thyroiditis Eur. J. Endocrinol., July 1, 2005; 153(1): 41 - 48. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Cafforio, F. Dammacco, A. Gernone, and F. Silvestris Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells Carcinogenesis, May 1, 2005; 26(5): 883 - 891. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Horiguchi, M. Sumitomo, J. Asakuma, T. Asano, T. Asano, and M. Hayakawa 3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Inhibitor, Fluvastatin, as a Novel Agent for Prophylaxis of Renal Cancer Metastasis Clin. Cancer Res., December 15, 2004; 10(24): 8648 - 8655. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-A. Shibata, Y. Ito, J. Morimoto, and Y. Otsuki Lovastatin inhibits tumor growth and lung metastasis in mouse mammary carcinoma model: a p53-independent mitochondrial-mediated apoptotic mechanism Carcinogenesis, October 1, 2004; 25(10): 1887 - 1898. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. K. Liao Statin Therapy: Having the Good Without the Bad Hypertension, June 1, 2004; 43(6): 1171 - 1172. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Ye, C. Wang, R. Sumpter Jr., M. S. Brown, J. L. Goldstein, and M. Gale Jr. Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation PNAS, December 23, 2003; 100(26): 15865 - 15870. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. L. Sabichi, M.-F. Demierre, E. T. Hawk, C. E. Lerman, and S. M. Lippman Frontiers in Cancer Prevention Research Cancer Res., September 15, 2003; 63(18): 5649 - 5655. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
